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Abstract
Objective—To estimate rates of recurrent TB due to reinfection and relapse, by HIV-status, in a
general population.
Design—Long-term cohort study in Karonga district, rural Malawi
Methods—All TB patients with culture-proven disease in Karonga district were followed-up
after treatment. HIV testing was offered and all M.tuberculosis isolates were fingerprinted using
IS6110 RFLP. Fingerprints from initial and recurrent disease episodes were compared to
distinguish relapse and reinfection: a second episode was considered a relapse if the fingerprint
was identical or differed by only 1-4 bands and was the first occurrence of that pattern in the
population. Rates of and risk factors for recurrence, reinfection disease, and relapse were
estimated using survival analysis and Poisson regression.
Results—584 culture-positive episodes of TB were diagnosed and completed treatment in
1995-2003 in patients with known HIV status; 53 culture-positive recurrences occurred by May
2005. Paired fingerprints were available for 39 of these. Reinfections accounted for 1/16
recurrences in HIV-negatives and 12/23 in HIV-positives. Rates of relapse were similar in HIV-
positive and HIV-negative individuals. Using multiple imputation to allow for missing fingerprint
information, the rate of reinfection disease in HIV-positives was 2.2/ 100 person years, and in
HIV-negatives 0.4/100 person years.
Conclusions—HIV increases the rate of recurrent TB in this setting by increasing the rate of
reinfection disease, not relapse.
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Introduction
In sub-Saharan Africa, rates of tuberculosis (TB) recurrence after treatment completion of
up to 20/100 person years are reported1. Recurrent TB occurs due to relapse of persistent
infection despite symptomatic and microbiological “cure”, or due to reinfection. Estimates
of which predominate are inconsistent2, and vary between populations with different
treatment regimens and infection risks. Clarification is important for monitoring the
effectiveness of control programmes, and for understanding immune responses to TB.
Relapse can be distinguished from reinfection disease by molecular fingerprinting strains
from successive episodes.
The impact of HIV on rates of relapse and reinfection disease is not clear. A Cape Town
study reported that 77% (24/31) of recurrences in a cohort suspected to have low HIV-
prevalence were due to reinfection3, and the incidence of reinfection disease exceeded that
of primary TB. If this were a generalised phenomenon, and not limited to individuals with
unusual susceptibility or exposure, this has implications for vaccine development: if natural
infection does not prevent subsequent infection, then an effective vaccine has to induce
some “unnatural” immune response. However, in another study in South Africa, recurrent
disease due to reinfection was common in HIV-positive and rare in HIV-negative
goldminers, while rates of relapse were similar4. Other studies have examined the
proportion of recurrences due to reinfection, but not calculated rates5-8.
We present results from the first study of relapse and reinfection disease to calculate rates by
HIV-status in a general population, and show that rates of reinfection, but not relapse, differ
by HIV-status.
Methods
The study was conducted in Karonga, a rural district in Malawi, population approximately
250,000. In 1998-2001, adult HIV prevalence was 14%9 and the annual incidence of smear-
positive pulmonary TB in adults was around 100/100,00010. Antiretroviral therapy was not
available in the district during the study.
TB case ascertainment was through enhanced passive surveillance; major health facilities
are staffed by project staff and remote health centres visited bi-monthly. TB suspects with
chronic cough have three sputa collected according to Malawi National TB Programme
(NTP) guidelines and undergo standard smear (auramine and Ziehl-Neelson) and culture
(acidified Lowenstein-Jensen slopes). A UK reference laboratory undertakes species
confirmation and drug sensitivities. Suspected extrapulmonary TB is investigated with
appropriate specimens.
Treatment follows the NTP schedule: prior to 1997, for smear-positive patients, 2 months of
streptomycin, isoniazid, rifampicin and pyrazinamide (2SHRZ) plus 6 months of
thiacetazone and isoniazid (6 TH). In 1997 ethambutol (E) was substituted for thiacetazone
and in 2001 for streptomycin. For smear-negative patients the course was 1SHT/11TH until
1997, then 1SHE/11EH until 2001, then 2HRZ/6EH. Two review sputum specimens are
collected at each of 2, 5 and 8 months of treatment for smear-positive patients.
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Patients were followed throughout treatment and outcomes recorded. Patients with culture-
positive TB were included if their initial episode of TB was diagnosed between September
1995 and March 2003 and if they completed treatment without change of regimen, thus
including some who were smear-positive (“failed”) at two months in whom the intensive
treatment phase was prolonged without re-treatment being started. Pulmonary TB patients
were “cured” if their end of treatment review specimens were negative on smear and culture.
Outcomes to the end of the study (May 2005) were ascertained from community-study
databases, and from home visits for those with uncertain vital status. Further episodes of TB
were ascertained through usual procedures. (The Karonga Prevention Study has developed
high quality tracing procedures which reliably identify individuals over decades, even after
migration)11.
Isolates confirmed as M.tuberculosis were subcultured and DNA extracted for fingerprinting
(RFLP typing of IS611012). Strains with fewer than 5 bands were spoligotyped. Strains
were compared, using Gelcompar™ and visually. Beijing strains were identified by
comparison of RFLP patterns and confirmed using spoligotyping13. Recurrences with
identical strains, or with changes of 1-4 bands on RFLP where the new pattern was the first
occurrence of that pattern in the population, were defined as relapses14,15. Changes of more
than 4 bands or differences of 1-4 bands where the second pattern had been found in
previous patients were taken as evidence of reinfection. In addition, comparisons to strains
processed on the same day were made, if reinfection disease was suspected, to exclude
contamination15. Cross-contamination is more likely in an isolated positive culture (IPC;
single positive culture from a patient with no other specimens smear or culture-positive);
these were included but are indicated in the table.
Strain comparison was carried out blind to patient HIV-status. The frequency of each strain
in the population was noted16. Drug sensitivity patterns (streptomicin, isoniazid, rifampicin,
ethambutol and pyrazinamide (S,H,R,E,Z)) were recorded.
TB patients were counselled for HIV testing if consent was given on initiation of treatment.
In cases where an HIV test from the time of treatment initiation was not available, HIV
status was inferred from a prior positive or a subsequent negative test.
Data are presented on the 584 individuals with known HIV status, with the exception of the
univariable analysis of risk factors and the analysis of Beijing strains, for which knowledge
of HIV status is not required.
Survival analysis and Poisson regression were used. To estimate recurrence rates, follow-up
was censored at time of death, at time of departure from district or loss to follow up, at the
time of diagnosis with recurrent TB, or at the end of the study, whichever came first. All
those treated for recurrent TB were censored at diagnosis, but if they were culture positive,
re-entered the analysis when they completed treatment. Robust standard errors were used to
account for non-independence of multiple episodes.
To improve estimates of culture-positive relapse and reinfection disease rates, multiple
imputation of relapse/reinfection disease status was done for the 14 culture-positive
recurrences for which paired fingerprint data were not available. Five imputations were
done, using a logistic regression model including age group, sex, HIV status, drug resistance
of the intial episode, and timing of the recurrence to predict if the recurrence was a relapse
or reinfection, and combined in a Poisson regression analysis to estimate (i) the rate of
relapse and reinfection, by HIV status and time since completion of the previous episode of
TB (ii) the rate ratio for relapse and reinfection, comparing HIV-positive to HIV-negative
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individuals, controlling for age group, sex, and time since completion of the previous
episode of TB.
The studies were approved by the National Health Sciences Research Committee of Malawi
and the London School of Hygiene and Tropical Medicine Research Ethics Committee.
Results
From September 1995 to March 2003 there were 1287 episodes of culture-positive TB
diagnosed. HIV-status of patient was available in 780 cases (510 (65%) were HIV-positive)
of which 584 (75%) completed treatment: (HIV-positive, 67% and HIV-negative, 89%)
(Figure 1). Other episodes resulted in transfer or default from treatment (76, 10%) or death
(120, 15%) with higher rates, in the HIV-positive patients.
One patient was known to have seroconverted during the period of the study, between
between initiation of treatment of first and second (culture-negative) episode, 3 years later.
She was included as HIV-negative when overall rates of recurrence were calculated to avoid
numerator/denominator bias as seroconvertors without recurrences might not be identified.
For the 537/584 pulmonary episodes, 360 (67%) had smear-negative 8 month sputa; the
other patients could not produce sputum. The 584 episodes occurred in 558 people. 47
episodes (8%) were in people who had previously been treated for TB. 59% of the episodes
were in females, and the median age at recruitment was 33 years for females and 37 for
males.
For 11 of the 584 episodes, no further information was available after treatment completion.
The remaining 573 contributed 1646 person years (py) of follow-up (HIV-negative 871 py,
HIV-positive 775 py). At the end of the study period, 208 (87%) HIV-negative patients were
alive, 15 (6%) had died and 17 (7%) had left the district. For HIV-positive patients the
numbers were 143 (42%) alive, 180 (52%) died and 21 (6%) left.
Mortality
The mortality was much higher in HIV-positive than HIV-negative TB patients post-
treatment with less than 50% surviving beyond 3 years compared to more than 95%.
Recurrent TB
During follow-up from September 1995 to May 2005, the 584 episodes were followed by 88
clinically-diagnosed recurrences, of which 53 were culture-positive; the remainder were
culture-negative on two or more specimens. The overall rate of recurrence was higher in
HIV-positive than in HIV-negative individuals (RR 2.1, p=0.002 adjusted for age, sex and
time since treatment completion) but not when restricted to culture-positive recurrence (adj.
RR 1.4, p=0.22 & Figure 2a).
In 39/53 of the culture-positive recurrences, RFLP data were available from both episodes.
This included 16/22 recurrences in HIV-negatives and 23/31 in HIV-positives (Figure 1).
Details of paired episodes are presented in Table 1, ordered by HIV-status and increasing
time since completion of treatment for index episode: 26 cases were relapses and 13
reinfections. Three of the “relapses” were in people who were culture-positive (but smear-
negative) at the end of treatment but are included as relapses rather than treatment failures,
as under standard NTP conditions, smear-negativity is the marker for “cure” and culture is
not routine. Table 1 also presents data relevant to the accuracy of the classification of
relapse and reinfection: number of bands, whether the band pattern had changed, presence of
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IPC, and population frequency of the second strain. Over this period 494 distinct strains
were identified in the district, the most common strain accounting for 4.1% of isolates.
Among the 14 recurrences without paired RFLP data, 5 had the fingerprint missing from the
initial episode and 9 from the recurrent episode.
Relapses are shown in figure 2b: 15 relapses occurred in HIV-negative patients (11
confirmed HIV-negative at relapse, 4 refused further testing) and 11 in HIV-positive
patients. The rate of relapse was highest in the first 6 months, and was similar for HIV-
positive and HIV-negative individuals (adj RR 0.8, p=0.48). The people who had two
episodes of culture-positive recurrence (Table 1, “A” and “B”) were HIV-negative, and all
four episodes were confirmed relapses.
Recurrences due to reinfection (when possibilities of cross-contamination were excluded)
occurred in 1 HIV-negative patient (confirmed HIV-negative at recurrence) and 12 HIV-
positive patients. There was a steady rate of reinfection disease for HIV-positive individuals
from the early months post-treatment and no reinfection disease in the HIV-negative patients
until one case more than 4 years after treatment (Figure 2c). The rate of culture-positive
reinfection disease was higher in HIV-positive than in HIV-negative patients (adj RR 7.5,
p=0.041). Restricting the definition of relapse to those with exactly matching fingerprints,
one HIV-negative case with recurrence at two months and one HIV-positive case at one
month would be reclassified as reinfection disease (Table 1).
Beijing strains
Thirty one of the 759 initial episodes (4.1%) involved Beijing genotype strains. None were
followed by proven relapses, one was followed by reinfection disease and one by culture-
negative recurrence. Three of the 14 episodes of reinfection disease (21%, 95% ci 5-51%)
were due to Beijing strains, including the single case in an HIV-negative patient (Table 1).
Though numbers are small, there are more than expected; only 4.3% of patients had Beijing
strains in their first episode of disease over this period13, giving a relative risk of Beijing
strain associated with reinfection disease of 4.6 (95% ci 1.6-13.0) when adjusted for year.
Risk factors for recurrence
Table 2 shows rates and (univariable) rate ratios for culture-positive recurrence, relapse and
reinfection. Rates of recurrent culture-positive TB, and reinfection disease were higher in
HIV-positive patients, but rates of relapse were not. Recurrence rates were also higher in
women, those who had had previous TB, those with drug resistance, and those who had a
smear-positive specimen during treatment. Time since treatment completion was a strong
determinant of relapse vs. reinfection, with high rates of relapse in the first 6 months. There
was no evidence of an association between HIV-status and relapse when adjusted for other
factors, or when early and late relapses were considered separately. Overall, there remained
a strong association (RR=5.4, 95% ci 2.1-14.1) between drug resistance and relapse when
adjusted for other factors.
Rates of reinfection disease and relapse by HIV
Rates of recurrence, relapse and reinfection disease by HIV-status are shown in Table 3,
with and without imputed data. Including imputed data, the overall rates of relapse were
2.1/100 py for HIV-negative and 1.8/100py for HIV-positive patients, although rates were
not constant over the period of the study with high initial rates and substantial decline after
six months. The rates of reinfection disease were estimated as 0.4/100py for HIV-negative
and 2.2/100py for HIV-positive patients, and, although low in the first six months, appeared,
with these few data, to be fairly constant thereafter. Adjusted for age, sex and timeband (to
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account for differing rates over time) the rate ratio for relapse comparing HIV-positive
patients to HIV-negative patients, was 0.8 (0.3-1.7, p=0.48) and for reinfection, 6.3
(1.3-31.5, p=0.02).
Discussion
We demonstrate that rates of relapse, given successful completion of treatment under routine
programme conditions in Karonga, are not influenced by HIV-status, in contrast to the rate
of reinfection disease. In HIV-positive individuals the rate of reinfection disease was equal
to the rate of relapse, but the rate of reinfection disease in HIV-negative individuals was
very low. Apart from HIV, the major predictor of relapse or reinfection disease was time
since completion of treatment as different causes of recurrence predominated in different
time periods.
A considerable proportion of diagnosed culture-positive patients were not HIV tested (39%).
These were predominantly (65%) amongst those who failed to complete treatment due to
death or default and thus would not contribute to rates of recurrence. Of those who
completed treatment and were eligible for this study, the majority of the 175 (23%) who
were not tested for HIV, were diagnosed in years when KPS TB studies were quiescent,
unrelated to individual patient characteristics. Rates of mortality after treatment completion,
recurrence, relapse and reinfection for HIV-unknown patients were intermediate when
compared to rates for HIV-negative and HIV-positive, which is consistent with there being
no important bias introduced.
People who initially refused testing but were later found HIV-negative (in two cases, at time
of recurrence) were included for analysis in the HIV-negative group. Thus rates of
recurrence in HIV-negatives might be slightly inflated.
Whereas the missing RFLP results did not affect the estimates of the rate ratios (as shown by
the similarity before and after addition of imputed values), they give a more realistic
estimate of the absolute rates of relapse and reinfection, which would otherwise be
underestimated because of the missing data.
Missing RFLP fingerprints were more frequent at the beginning of the study period due to
technical difficulties in recovering stored cultures, again unrelated to patient characteristics,
with equal proportions missing for HIV-positive and HIV-negative patients. Given the
methods of ascertainment and follow-up of TB cases in Karonga there should be no
difference in whether recurrent cases were identified or patients lost to followup, by HIV-
status.
Our findings are similar to those in South African goldminers4, despite the different setting
and much lower TB incidence in Malawi. The predominance of relapse as a cause of
recurrence in HIV-negative individuals is consistent with two studies from high TB
prevalence settings: in Hong Kong 37/42 recurrences17, and in Vietnam 39/50 recurrences
had identical strains18. However, findings from two other studies where HIV prevalence is
unknown but thought to be low, differed considerably: 32/52 recurrences in Shanghai19 and
24/31 in Cape Town3 were considered reinfections. In Cape Town the incidence of TB is
extremely high, three times that of Karonga, while the incidence in China is similar to
Malawi. In each of these studies, the HIV prevalence may have been considerably higher in
those with reinfection disease than in the population, and among TB patients in general, and
there may be other important risk factors, such as alcohol use. There may also be
methodological reasons for the differences.
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Errors of patient identification, sample handling, or cross-contamination will favour
“reinfections”; wrongly attributed specimens in either episode are unlikely to match. In
addition, apparent reinfections could be due to mixed infections20-23. Wrongly classifying
“relapse” is unlikely, unless there is homogeneity in the molecular fingerprints of circulating
strains. The potential for misclassification based on IPC is higher17,24,25. In this study
none of the HIV-negative patients with recurrences had IPC. Among the HIV-positives with
recurrences, 3 individuals had IPC in initial strains and 1 in recurrent strains, 1 classifed as
relapse, 3 as reinfections (Table 1); thus, if anything, we overestimated reinfection disease
rates, although none of the IPC were processed on the same day as an isolate with the same
strain. The longstanding population-based epidemiological studies in Karonga District make
incorrect patient identification very unlikely, and sample handling procedures are rigorous.
Forty four percent (46/105) of recurrent episodes of TB were culture negative and diagnosed
clinically or radiographically. Radiographic changes may be unreliable in this group as signs
of previous TB are often unresolved. This compares with 51% (1352/2639) of episodes from
the recruitment period who were excluded from the cohort as there was no positive culture.
HIV positive patients were more likely at both initial (54%, 597/1107) and recurrent
episodes (47%, 27/58) to have a diagnosis of culture negative TB than were HIV negative
patients (50%, 268/538 and 27%, 8/30 respectively).
Although higher rates of relapse might be expected in HIV-positive patients, as effective
chemotherapy needs support from a functioning immune system, this may be counter-
balanced by the lower rates of cavitatory disease, associated with relapse4.
Immunosuppression may also increase the proportion of culture-negative and undiagnosed
TB, and will increase mortality rates. There will be true relapses (and reinfections) among
the culture-negative recurrences and deaths. Cause of death was unknown for most patients,
but 4/11 HIV-negative patients and 53/145 HIV-positive patients who died without having
been diagnosed with recurrent TB, had submitted sputa post-treatment suggesting that they
had had symptoms consistent with TB: all were negative. Five (all HIV-positive) submitted
sputa within three months of death. HIV-positive patients with drug resistant isolates were
twice as likely to die during treatment as those with sensitive strains (p=0.02), but there were
few deaths in HIV-negative patients during treatment whether or not there was a drug
resistant strain, and drug resistance is rare in this setting.
Most of the relapses were early and might be identified as treatment failures prior to
treatment completion, if more sensitive clinical and laboratory investigations were available.
HIV may exert its effect on reinfection disease by increasing risk of re-infection with M.
tuberculosis after treatment, increasing risk of development of disease given re-infection, or
both. HIV-infection may also increase the risk of exposure, through attendance at health
facilities.
High rates of HIV-negative reinfection disease would imply that previous disease does not
induce protective immunity at least in a proportion of individuals known to be susceptible to
TB26,27. Using our previous estimates of year and age specific rates of TB and of HIV
prevalence in the district10,28, less than one new primary case of TB would be expected
among an HIV-negative group age- sex- and area-matched to the population in this study.
One HIV-negative reinfection case was found. Though numbers are small, this is consistent
with natural TB providing little or no protection against subsequent infection and disease,
and with the hypothesis that individuals who have one episode of disease are at increased
risk of another3.
Beijing genotype strains have been associated with higher recurrence rates29 30; although in
one study the association was lost after controlling for drug resistance. In our study, we
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found no association with relapse rates. However, the single confirmed HIV-negative
reinfection disease case was due to a Beijing strain, and overall the Beijing genotype was
over-represented among reinfection disease cases. This could represent a higher probability
of a Beijing strain establishing infection; faster progression to disease, given reinfection
(consistent with findings in the Gambia31); or a chance finding. In South African
goldminers, 3/14 reinfection disease strains were Beijing32, and areas where Beijing strain
prevalence is high report high rates of reinfection disease in HIV-negative patients 33,34.
The mortality during treatment in the HIV-positive patients with reinfection disease episodes
was high (5/11) and these findings strengthen the case for secondary prophylaxis for HIV-
positive TB patients. CD4 counts were not available to estimate the risk of recurrence at
different levels of immunosuppression. While 9/10 recurrences by 6 months post-treatment
amongst HIV-positive patients were relapses, 10/12 thereafter were reinfections, perhaps
because immunocompromised patients who have residual bacilli after treatment will relapse
early on. Secondary prophylaxis could thus be delayed to avoid inducing drug resistance, but
still prevent reinfection disease. The rates of reinfection disease were not so high as to
suggest that there is a greater risk after TB treatment than at other times in the course of HIV
infection, and primary preventive therapy based on CD4 count is an alternative, adding to
the protection assumed to be afforded by antiretroviral therapy35.
Identifying underlying reasons for the higher recurrence rate in HIV-positive than in HIV-
negative individuals is important operationally. Relapse rates vary according to drug
regimens, programme effectiveness and prevalence of drug resistant strains; reinfection
disease rates will vary according to background risk of M.tuberculosis infection. Our
findings are consistent with another cohort study in a contrasting setting, and emphasise that
in an area of medium to high TB incidence, HIV-negative patients are predominantly
affected by relapse, while HIV-positive patients are at risk of both relapse and reinfection.
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Figure 1.
Outcome of episodes of culture positive tuberculosis
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Figure 2.
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